These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 32961647)

  • 1. Development of a Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-7/-13 Inhibitor.
    Fischer T; Riedl R
    Molecules; 2017 Sep; 22(9):. PubMed ID: 32961647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted Polypharmacology: Discovery of a Highly Potent Non-Hydroxamate Dual Matrix Metalloproteinase (MMP)-10/-13 Inhibitor.
    Senn N; Ott M; Lanz J; Riedl R
    J Med Chem; 2017 Dec; 60(23):9585-9598. PubMed ID: 28953404
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective enhancement of collagenase-mediated cleavage of resident type II collagen in cultured osteoarthritic cartilage and arrest with a synthetic inhibitor that spares collagenase 1 (matrix metalloproteinase 1).
    Dahlberg L; Billinghurst RC; Manner P; Nelson F; Webb G; Ionescu M; Reiner A; Tanzer M; Zukor D; Chen J; van Wart HE; Poole AR
    Arthritis Rheum; 2000 Mar; 43(3):673-82. PubMed ID: 10728762
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a truncated recombinant form of human membrane type 3 matrix metalloproteinase.
    Shimada T; Nakamura H; Ohuchi E; Fujii Y; Murakami Y; Sato H; Seiki M; Okada Y
    Eur J Biochem; 1999 Jun; 262(3):907-14. PubMed ID: 10411655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Battle tactics against MMP-9; discovery of novel non-hydroxamate MMP-9 inhibitors endowed with PI3K/AKT signaling attenuation and caspase 3/7 activation via Ugi bis-amide synthesis.
    Ayoup MS; Fouad MA; Abdel-Hamid H; Ramadan ES; Abu-Serie MM; Noby A; Teleb M
    Eur J Med Chem; 2020 Jan; 186():111875. PubMed ID: 31740054
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays.
    Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T
    Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A dual inhibitor of matrix metalloproteinases and a disintegrin and metalloproteinases, [¹⁸F]FB-ML5, as a molecular probe for non-invasive MMP/ADAM-targeted imaging.
    Matusiak N; Castelli R; Tuin AW; Overkleeft HS; Wisastra R; Dekker FJ; Prély LM; Bischoff R; van Waarde A; Dierckx RA; Elsinga PH
    Bioorg Med Chem; 2015 Jan; 23(1):192-202. PubMed ID: 25438884
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydroxamate-based peptide inhibitors of matrix metalloprotease 2.
    Jani M; Tordai H; Trexler M; Bányai L; Patthy L
    Biochimie; 2005; 87(3-4):385-92. PubMed ID: 15781326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dysregulated miR-127-5p contributes to type II collagen degradation by targeting matrix metalloproteinase-13 in human intervertebral disc degeneration.
    Hua WB; Wu XH; Zhang YK; Song Y; Tu J; Kang L; Zhao KC; Li S; Wang K; Liu W; Shao ZW; Yang SH; Yang C
    Biochimie; 2017 Aug; 139():74-80. PubMed ID: 28559201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Matrix metalloproteinase inhibitors.
    Wojtowicz-Praga SM; Dickson RB; Hawkins MJ
    Invest New Drugs; 1997; 15(1):61-75. PubMed ID: 9195290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties.
    Okada Y; Morodomi T; Enghild JJ; Suzuki K; Yasui A; Nakanishi I; Salvesen G; Nagase H
    Eur J Biochem; 1990 Dec; 194(3):721-30. PubMed ID: 2269296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of membrane-type 1 matrix metalloproteinase by hydroxamate inhibitors: an examination of the subsite pocket.
    Yamamoto M; Tsujishita H; Hori N; Ohishi Y; Inoue S; Ikeda S; Okada Y
    J Med Chem; 1998 Apr; 41(8):1209-17. PubMed ID: 9548812
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human fibronectin and MMP-2 collagen binding domains compete for collagen binding sites and modify cellular activation of MMP-2.
    Steffensen B; Xu X; Martin PA; Zardeneta G
    Matrix Biol; 2002 Aug; 21(5):399-414. PubMed ID: 12225805
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 45 kDa collagen-binding fragment of fibronectin induces matrix metalloproteinase-13 synthesis by chondrocytes and aggrecan degradation by aggrecanases.
    Stanton H; Ung L; Fosang AJ
    Biochem J; 2002 May; 364(Pt 1):181-90. PubMed ID: 11988091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer.
    Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA
    Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent and selective 2-naphthylsulfonamide substituted hydroxamic acid inhibitors of matrix metalloproteinase-13.
    Tommasi RA; Weiler S; McQuire LW; Rogel O; Chambers M; Clark K; Doughty J; Fang J; Ganu V; Grob J; Goldberg R; Goldstein R; Lavoie S; Kulathila R; Macchia W; Melton R; Springer C; Walker M; Zhang J; Zhu L; Shultz M
    Bioorg Med Chem Lett; 2011 Nov; 21(21):6440-5. PubMed ID: 21937229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MMP-2 selectivity in hydroxamate-type inhibitors.
    Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B
    Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Turnover of type II collagen and aggrecan in cartilage matrix at the onset of inflammatory arthritis in humans: relationship to mediators of systemic and local inflammation.
    Fraser A; Fearon U; Billinghurst RC; Ionescu M; Reece R; Barwick T; Emery P; Poole AR; Veale DJ
    Arthritis Rheum; 2003 Nov; 48(11):3085-95. PubMed ID: 14613270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Notch pathway mediates the angiotensin II-induced synthesis of extracellular matrix components in podocytes.
    Yao M; Wang X; Wang X; Zhang T; Chi Y; Gao F
    Int J Mol Med; 2015 Jul; 36(1):294-300. PubMed ID: 25902289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors.
    Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P
    Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.